CA2991921C - Methotrexate for proliferative vitreoretinopathy - Google Patents

Methotrexate for proliferative vitreoretinopathy Download PDF

Info

Publication number
CA2991921C
CA2991921C CA2991921A CA2991921A CA2991921C CA 2991921 C CA2991921 C CA 2991921C CA 2991921 A CA2991921 A CA 2991921A CA 2991921 A CA2991921 A CA 2991921A CA 2991921 C CA2991921 C CA 2991921C
Authority
CA
Canada
Prior art keywords
methotrexate
pvr
injection
injections
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2991921A
Other languages
English (en)
French (fr)
Other versions
CA2991921A1 (en
Inventor
Dean Eliott
Tomasz P. STRYJEWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Eye and Ear Infirmary
Original Assignee
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary filed Critical Massachusetts Eye and Ear Infirmary
Priority to CA3200870A priority Critical patent/CA3200870A1/en
Publication of CA2991921A1 publication Critical patent/CA2991921A1/en
Application granted granted Critical
Publication of CA2991921C publication Critical patent/CA2991921C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2991921A 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy Active CA2991921C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3200870A CA3200870A1 (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462030778P 2014-07-30 2014-07-30
US62/030,778 2014-07-30
PCT/US2015/042951 WO2016019165A1 (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3200870A Division CA3200870A1 (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy

Publications (2)

Publication Number Publication Date
CA2991921A1 CA2991921A1 (en) 2016-02-04
CA2991921C true CA2991921C (en) 2023-08-08

Family

ID=55218325

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2991921A Active CA2991921C (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy
CA3200870A Pending CA3200870A1 (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3200870A Pending CA3200870A1 (en) 2014-07-30 2015-07-30 Methotrexate for proliferative vitreoretinopathy

Country Status (6)

Country Link
US (4) US10098884B2 (cg-RX-API-DMAC7.html)
EP (3) EP3174540B9 (cg-RX-API-DMAC7.html)
JP (3) JP7097181B2 (cg-RX-API-DMAC7.html)
CA (2) CA2991921C (cg-RX-API-DMAC7.html)
ES (2) ES2969374T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016019165A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991921C (en) * 2014-07-30 2023-08-08 Massachusetts Eye And Ear Infirmary Methotrexate for proliferative vitreoretinopathy
WO2018027044A1 (en) * 2016-08-05 2018-02-08 Schepens Eye Research Institute Idelalisib for treating proliferative vitreoretinopathy and abnormal intraocular neovascularization
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
WO2021051003A1 (en) 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
CN115804665A (zh) * 2022-12-13 2023-03-17 南昌大学附属眼科医院 一种tpvr动物模型的建立方法
WO2024129979A1 (en) * 2022-12-14 2024-06-20 Aldeyra Therapeutics, Inc. Methotrexate treatment methods
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032734A1 (en) 2000-07-26 2002-03-14 Rhoads Geoffrey B. Collateral data combined with user characteristics to select web site
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
JP5001645B2 (ja) * 2004-04-02 2012-08-15 電気化学工業株式会社 ヒアルロン酸−メトトレキサート結合体
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
MX2007003968A (es) * 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20090081277A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US20110200662A1 (en) 2008-10-22 2011-08-18 Arnold Glazier Method For The Treatment Of Proliferative Disorders Of The Eye
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US20140105956A1 (en) * 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CA2991921C (en) * 2014-07-30 2023-08-08 Massachusetts Eye And Ear Infirmary Methotrexate for proliferative vitreoretinopathy

Also Published As

Publication number Publication date
ES2969374T3 (es) 2024-05-17
EP3174540A1 (en) 2017-06-07
US10828306B2 (en) 2020-11-10
CA3200870A1 (en) 2016-02-04
CA2991921A1 (en) 2016-02-04
EP4311575A3 (en) 2024-04-03
US10272089B2 (en) 2019-04-30
WO2016019165A1 (en) 2016-02-04
US10098884B2 (en) 2018-10-16
JP2021059554A (ja) 2021-04-15
JP2017523974A (ja) 2017-08-24
US20200085827A1 (en) 2020-03-19
EP3791883A1 (en) 2021-03-17
US20210283135A1 (en) 2021-09-16
EP3174540B9 (en) 2021-05-05
JP2023145527A (ja) 2023-10-11
JP7097181B2 (ja) 2022-07-07
US20170368067A1 (en) 2017-12-28
EP4311575A2 (en) 2024-01-31
EP3174540B1 (en) 2020-09-02
EP3174540A4 (en) 2018-04-04
EP3791883B1 (en) 2023-10-25
US20170216294A1 (en) 2017-08-03
ES2835499T3 (es) 2021-06-22

Similar Documents

Publication Publication Date Title
US10828306B2 (en) Methotrexate for proliferative vitreoretinopathy
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
Kaufman et al. Cataract extraction in patients with pars planitis
Eperon et al. A biodegradable drug delivery system for the treatment of postoperative inflammation
JP2024103501A (ja) 被験体における虚血再灌流障害のリスクを予防又は軽減するための神経保護特性がある薬物の使用
US20230310446A1 (en) Rho kinase inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
Stewart et al. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery
US20130156841A1 (en) Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
İnan et al. Prevention of posterior capsule opacification by retinoic acid and mitomycin
Sandoval et al. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation
Chang et al. Two clinical trials of an intraocular steroid delivery system for cataract surgery
HK40049263B (en) Methotrexate for proliferative vitreoretinopathy
HK40049263A (en) Methotrexate for proliferative vitreoretinopathy
HK1236395A1 (en) Methotrexate for proliferative vitreoretinopathy
HK1236395B (en) Methotrexate for proliferative vitreoretinopathy
Kanclerz Toxic anterior segment syndrome after an uncomplicated vitrectomy with epiretinal membrane peeling
Alam et al. Comparison of a Preservative-free Non-steroidal Anti-inflammatory Drug and Preservative-free Corticosteroid after Uneventful Cataract Surgery: A Randomized Control Trial
RU2310452C1 (ru) Способ иммунореабилитации при лечении воспалений переднего отрезка глаза
AL MOHAIMEED Glaucoma Escalation after Penetrating Keratoplasty
TESAVIBUL RECURRENT HERPES SIMPLEX KERATITIS IN PENETRATING KERATOPLASTY
Gumus Topical Coenzyme Q10 Eye Drops as an Adjuvant Treatment in Challenging Refractory Corneal Ulcers: A Case Series and

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200617

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250725

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250828